Tiludronate
Based on 1 publication(s) in Google Scholar
Tiludronate (Tiludronic Acid), an orally active bisphosphonate, can act an osteoregulator. Tiludronate is used for the research of the metabolic bone disorders. Tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. Antiresorptive and anti-inflammatory properties.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 89987-06-4
- 화학식: C7H9ClO6P2S
- 분자량:318.61
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocol
- 순도&문서
- References
-
Help & FAQs
-
HY-17421
TenatoprazoleProton Pump Inhibitor -
HY-101664
IlaprazoleProton Pump Inhibitor -
HY-103261
SCH28080H+/K+-ATPase Inhibitor -
HY-135474
KM91104v-ATPase a3-B2 Inhibitor -
HY-118115
PyrabactinABA Agonist -
HY-13662B
(R)-LansoprazoleProton Pump Inhibitor -
HY-B1446
Esomeprazole magnesiumH+, K+-ATPase Inhibitor -
HY-B2145
Ilaprazole sodiumProton Pump Inhibitor -
HY-100560S
Abscisic acid-d6Stable Isotope -
HY-109079
AbeprazanProton Pump/Potassium-competitive Acid Inhibitor -
HY-17022
Esomeprazole magnesium trihydrateH+, K+-ATPase Inhibitor -
HY-109079A
Abeprazan hydrochlorideProton Pump/Potassium-competitive Acid Inhibitor
Publications Citing Use of MedChemExpress (MCE) Tiludronate
More
Biological Activity
제품 설명
In Vitro
The ability of Tiludronate to inhibit proton transport is 5-fold higher in kidney-derived vesicles (IC50=1.1 mM) and 10,000-fold higher in vesicles derived from osteoclasts (IC50=466 nM). Tiludronate also potently inhibited proton transport in yeast microsomal preparations (IC50=3.5 microM) and inhibited the activity of purified yeast V-ATPase. The inhibition of the osteoclast V-ATPase-mediated proton transport by Tiludronate is rapid, pH-dependent, and reversible[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 89987-06-4
-
분자량 318.61
-
화학식 C7H9ClO6P2S
-
SMILES
O=P(O)(O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1
-
Synonyms
Tiludronic acid
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep
ZDHHC3-mediated SCAP S-acylation promotes cholesterol biosynthesis and tumor immune escape in hepatocellular carcinoma. [Abstract]2024 Nov 9;43(11):114962. PMID: 39522165
순도&문서
References
[1]. Reginster JY, et al. Prevention of postmenopausal bone loss by tiludronate. Lancet. 1989;2(8678-8679):1469-1471. [Content Brief]
[2]. Nunes NLT, et al. Effects of local administration of tiludronic acid on experimental periodontitis in diabetic rats. J Periodontol. 2018;89(1):105-116. [Content Brief]
[3]. Bonjour JP, et al. Tiludronate: bone pharmacology and safety. Bone. 1995;17(5 Suppl):473S-477S. [Content Brief]
[4]. David P, et al. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. J Bone Miner Res. 1996;11(10):1498-1507. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Tiludronate Related Classifications
HY-A0213 Related Classifications
Powered by Bioz